Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 1
1974 1
1975 1
1980 1
1983 1
1985 1
1993 1
1994 1
1995 1
1997 1
1998 2
2000 1
2001 3
2003 3
2005 1
2007 2
2009 3
2010 2
2011 1
2012 2
2013 1
2015 1
2016 1
2018 1
2019 5
2020 3
2021 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lip and Oral Cavity Carcinoma"
Page 1
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. Cohen EEW, et al. J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. J Immunother Cancer. 2019. PMID: 31307547 Free PMC article. Clinical Trial.
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths …
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, …
5-Aminolevulinic acid photodynamic therapy for early-stage lip squamous cell carcinoma.
Wang P, Zhang G, Zhang L, Zhou Z, Shi L, Zeng Q, Zhu L, Wang X. Wang P, et al. Photodiagnosis Photodyn Ther. 2021 Sep;35:102321. doi: 10.1016/j.pdpdt.2021.102321. Epub 2021 May 17. Photodiagnosis Photodyn Ther. 2021. PMID: 34015543
BACKGROUND: Squamous cell carcinoma (SCC) of the lip removed by surgery may cause lip dysfunction and scar. ...However, few studies reported the use of topical ALA-PDT to manage lip SCC. METHODS: Between 2015 and 2017, 6 patients with Tis to T2 lip …
BACKGROUND: Squamous cell carcinoma (SCC) of the lip removed by surgery may cause lip dysfunction and scar. ...However, …
Oral field cancerization: current evidence and future perspectives.
Angadi PV, Savitha JK, Rao SS, Sivaranjini Y. Angadi PV, et al. Oral Maxillofac Surg. 2012 Jun;16(2):171-80. doi: 10.1007/s10006-012-0317-x. Epub 2012 Feb 22. Oral Maxillofac Surg. 2012. PMID: 22354325 Review.
This concept has been frequently used to explain the occurrence of multiple primary cancers and recurrences following complete excision of oral cancer. DISCUSSION: This review deals in detail with the origin, principle, various theories used to explain this effect a …
This concept has been frequently used to explain the occurrence of multiple primary cancers and recurrences following complete excisi …
Squamous cell carcinoma of the head and neck in children.
Dombrowski ND, Wolter NE, Irace AL, Robson CD, Perez-Atayde AR, Mack JW, Rahbar R. Dombrowski ND, et al. Int J Pediatr Otorhinolaryngol. 2019 Feb;117:131-137. doi: 10.1016/j.ijporl.2018.11.019. Epub 2018 Nov 20. Int J Pediatr Otorhinolaryngol. 2019. PMID: 30579067
Data pertaining to clinical presentation, diagnostic methods, treatment plan, complications, recurrence, follow-up, or outcome were collected. ...Lesions were identified in the oral cavity (n = 5, 45.5%), lip/upper lip (n = 3, 27.3%), lar …
Data pertaining to clinical presentation, diagnostic methods, treatment plan, complications, recurrence, follow-up, or outcome …
High-dose-rate brachytherapy using molds for lip and oral cavity tumors.
Unetsubo T, Matsuzaki H, Takemoto M, Katsui K, Hara M, Katayama N, Waki T, Kanazawa S, Asaumi J. Unetsubo T, et al. Radiat Oncol. 2015 Apr 8;10:81. doi: 10.1186/s13014-015-0390-z. Radiat Oncol. 2015. PMID: 25888772 Free PMC article.
BACKGROUND: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral cavity cancer. However, limited reports exist regarding the feasibility of this method. In this retrospective study, we evaluated the o …
BACKGROUND: High-dose-rate (HDR) brachytherapy using the mold technique is a less invasive treatment for early lip and oral …
Surgical management of lip carcinoma.
Campbell JP. Campbell JP. J Oral Maxillofac Surg. 1998 Aug;56(8):955-61. doi: 10.1016/s0278-2391(98)90658-9. J Oral Maxillofac Surg. 1998. PMID: 9710190 Review. No abstract available.
GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas.
Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, Polo A, Rovirosa A, Strnad V. Mazeron JJ, et al. Radiother Oncol. 2009 May;91(2):150-6. doi: 10.1016/j.radonc.2009.01.005. Epub 2009 Mar 28. Radiother Oncol. 2009. PMID: 19329209 Review.
Both primary and recurrent squamous cell carcinoma of the head and neck are classic indications for brachytherapy. ...The recommendations are then specified for the classical brachytherapy tumor sites following an analogue more focussed structure (patient selection, …
Both primary and recurrent squamous cell carcinoma of the head and neck are classic indications for brachytherapy. ...The reco …
Comparison of approaches for oral cavity cancer resection: lip-split versus visor flap.
Cilento BW, Izzard M, Weymuller EA, Futran N. Cilento BW, et al. Otolaryngol Head Neck Surg. 2007 Sep;137(3):428-32. doi: 10.1016/j.otohns.2007.05.006. Otolaryngol Head Neck Surg. 2007. PMID: 17765770
OBJECTIVE: To compare lip-split and visor flap approaches to the oral cavity in terms of morbidity, margins, and locoregional recurrence. ...METHODS: Seventy patients undergoing resection of advanced (T4) anterior oral cavity squamous cel …
OBJECTIVE: To compare lip-split and visor flap approaches to the oral cavity in terms of morbidity, margins, and locore …
Applications of brachytherapy in head and neck cancer.
Harrison LB. Harrison LB. Semin Surg Oncol. 1997 May-Jun;13(3):177-84. doi: 10.1002/(sici)1098-2388(199705/06)13:3<177::aid-ssu4>3.0.co;2-4. Semin Surg Oncol. 1997. PMID: 9143055 Review.
This is especially important in the head and neck. Resection of organs such as the lip, oral tongue, base-of-tongue, and other sites can cause significant functional and cosmetic morbidity. ...Therefore, brachytherapy becomes an important component of the treatment …
This is especially important in the head and neck. Resection of organs such as the lip, oral tongue, base-of-tongue, and other …
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, Bykowski J, Ellison CA, Black LJ, Thompson PA, Callejas-Valera JL, Lee JH, Cohen EEW, Spanos WC. Powell SF, et al. J Clin Oncol. 2020 Jul 20;38(21):2427-2437. doi: 10.1200/JCO.19.03156. Epub 2020 Jun 1. J Clin Oncol. 2020. PMID: 32479189 Free PMC article. Clinical Trial.
PURPOSE: Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands (PD-L1, PD-L2). Although pembrolizumab is approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), it …
PURPOSE: Pembrolizumab is a humanized monoclonal antibody that blocks interaction between programmed death receptor-1 (PD-1) and its ligands …
44 results